Terms: = Small Cell Lung Cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
725 results:
1. Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
Yamaguchi T; Shimizu J; Matsuzawa R; Watanabe N; Horio Y; Fujiwara Y
BMC Cancer; 2024 Jul; 24(1):842. PubMed ID: 39009968
[TBL] [Abstract] [Full Text] [Related]
2. SHR-A1811 (antibody-drug conjugate) in advanced her2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study.
Li Z; Song Z; Hong W; Yang N; Wang Y; Jian H; Liang Z; Hu S; Peng M; Yu Y; Wang Y; Jiao Z; Zhao K; Song K; Li Y; Shi W; Lu S
Signal Transduct Target Ther; 2024 Jul; 9(1):182. PubMed ID: 39004647
[TBL] [Abstract] [Full Text] [Related]
3. A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with her2 mutations.
Wang L; Wu Y; Ren Z; Chu X; Chen J; Liu L; Zhao J; Yu X; Xie M; Su C
Cancer Med; 2024 Jun; 13(12):e7335. PubMed ID: 38923311
[TBL] [Abstract] [Full Text] [Related]
4. Ultrasonic-responsive piezoelectric stimulation enhances sonodynamic therapy for her2-positive breast cancer.
Chen Z; Yang L; Yang Z; Wang Z; He W; Zhang W
J Nanobiotechnology; 2024 Jun; 22(1):369. PubMed ID: 38918812
[TBL] [Abstract] [Full Text] [Related]
5. Prolonged Response to Afatinib and Crizotinib in a Rare Case of
Plomer E; Früh M; Lauber A; Demmer I; Jochum W; Koster KL
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891886
[TBL] [Abstract] [Full Text] [Related]
6. Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer.
Zhang X; Zhang H; Hou F; Fang T; Zhang C; Wang H; Song S; Lan H; Wang Y; Hou H
World J Surg Oncol; 2024 Jun; 22(1):159. PubMed ID: 38890622
[TBL] [Abstract] [Full Text] [Related]
7. PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.
Sarova P; Mosleh B; Zehetmayer S; Oberndorfer F; Widder J; Prosch H; Aigner C; Idzko M; Hoda MA; Gompelmann D
Thorac Cancer; 2024 Jul; 15(20):1598-1606. PubMed ID: 38860475
[TBL] [Abstract] [Full Text] [Related]
8. Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.
de Jager VD; Cajiao Garcia BN; Kuijpers CCHJ; de Bock GH; Maas WJ; Timens W; van Kempen LC; van der Wekken AJ; Schuuring E; Willems SM
Eur J Cancer; 2024 Jul; 205():114125. PubMed ID: 38788285
[TBL] [Abstract] [Full Text] [Related]
9. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
[No Abstract] [Full Text] [Related]
10. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating her2 mutations (DESTINY-PanTumor01): an international, phase 2 study.
Li BT; Meric-Bernstam F; Bardia A; Naito Y; Siena S; Aftimos P; Anderson I; Curigliano G; de Miguel M; Kalra M; Oh DY; Park JO; Postel-Vinay S; Rha SY; Satoh T; Spanggaard I; Michelini F; Smith A; Machado KK; Saura C;
Lancet Oncol; 2024 Jun; 25(6):707-719. PubMed ID: 38710187
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
12. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Peters S; Loi S; André F; Chandarlapaty S; Felip E; Finn SP; Jänne PA; Kerr KM; Munzone E; Passaro A; Pérol M; Smit EF; Swanton C; Viale G; Stahel RA
Ann Oncol; 2024 Jul; 35(7):607-629. PubMed ID: 38648979
[TBL] [Abstract] [Full Text] [Related]
13. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-lung01): primary results of the her2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
[TBL] [Abstract] [Full Text] [Related]
14. [Advances in the treatment of anti-her-2 antibody drug conjugates in pan-tumor with low her-2 expression].
Wei T; Yuan P
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
[TBL] [Abstract] [Full Text] [Related]
15. her2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
Zhang H; Finkelman BS; Ettel MG; Velez MJ; Turner BM; Hicks DG
Histopathology; 2024 Jul; 85(1):3-19. PubMed ID: 38443321
[TBL] [Abstract] [Full Text] [Related]
16. EGFR and erbb2 Exon 20 Insertion Mutations in Chinese Non-small cell lung cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic treatment Evaluation.
Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
[TBL] [Abstract] [Full Text] [Related]
17. her2-Mutant Advanced and/or Metastatic Non-small-cell lung cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, treatment Practice Patterns, and Outcomes.
Waliany S; Neal JW; Engel-Nitz N; Lam C; Lin F; Park L; Le L; Nagasaka M
Clin Lung Cancer; 2024 Jun; 25(4):319-328.e1. PubMed ID: 38403548
[TBL] [Abstract] [Full Text] [Related]
18. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
[TBL] [Abstract] [Full Text] [Related]
19. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
[TBL] [Abstract] [Full Text] [Related]
20. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
Kim DW; Schram AM; Hollebecque A; Nishino K; Macarulla T; Rha SY; Duruisseaux M; Liu SV; Al Hallak MN; Umemoto K; Wesseler C; Cleary JM; Springfeld C; Neuzillet C; Joe A; Jauhari S; Ford J; Goto K
Future Oncol; 2024; 20(16):1057-1067. PubMed ID: 38348690
[TBL] [Abstract] [Full Text] [Related]
[Next]
